Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc.
- Market cap
- $4.18M
Your view on SBFMW
Overview
What the company does, where it operates, and who runs it.
About Sunshine Biopharma, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Steve N. Slilaty
- Headquarters
- 333 Las Olas Way, Fort Lauderdale, FL, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Steve N. Slilaty
- Headquarters
- 333 Las Olas Way, Fort Lauderdale, FL, US
Sunshine Biopharma, Inc. operates as a pharmaceutical and nutritional supplement company primarily dedicated to the research and development of innovative anticancer drugs. The company's pipeline includes Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin.
This compound is currently in development to address a broad spectrum of cancers, such as leukemia, lymphoma, and tumors affecting the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver.
Significantly, Adva-27a has also shown effectiveness against multidrug-resistant cancer cells, including those associated with pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma. Another key therapeutic in development is SBFM-PL4, an anti-coronavirus treatment compound.
In addition to its pharmaceutical endeavors, Sunshine Biopharma offers a range of nutritional supplements, including the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, and continues to develop and market other scientifically-formulated nutritional products.
The company has forged a licensing agreement with the University of Georgia to further the development of its lead anti-coronavirus compound, SBFM-PL4. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Sunshine Biopharma, Inc.. Starting points for Sunshine Biopharma, Inc.: EPS -$26.23, beta 1.31 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Sunshine Biopharma, Inc.. Trailing twelve-month EPS for Sunshine Biopharma, Inc. stands at -$26.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|
| Average estimate | −$5.80 | −$39.00 | −$8.00 |
| Lowest estimate | −$5.80 | −$39.00 | −$8.00 |
| Highest estimate | −$5.80 | −$39.00 | −$8.00 |
| Number of analysts | 1 | 1 | 1 |
| A year ago | −$3.001 | −$288.001 | — |
| Growth vs a year ago | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|
| Average estimate | $9.80M | $35.80M | $45.00M |
| Lowest estimate | $9.80M | $35.80M | $45.00M |
| Highest estimate | $9.80M | $35.80M | $45.00M |
| Number of analysts | 1 | 1 | 1 |
| A year ago | $8.58M | $36.31M | — |
| Growth vs a year ago | +14.3% | −1.4% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Sunshine Biopharma, Inc.. Sunshine Biopharma, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BFRIWBiofrontera Inc. | Healthcare | Medical - Pharmaceuticals | $796,653 | ||
| BHNGFBhang Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $23,476 | ||
| IONKFIonic Brands Corp. | Healthcare | Drug Manufacturers - Specialty & Generic | $1,592 | ||
| MDVLQMedAvail Holdings, Inc. | Healthcare | Medical - Pharmaceuticals | $161 | ||
| NRSNNeuroSense Therapeutics Ltd. | Healthcare | Biotechnology | $2.4M | ||
| SBFMSunshine Biopharma, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $4.7M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| INLBItem 9 Labs Corp. | Healthcare | OTC | $70,181 | ||
| INMInMed Pharmaceuticals Inc. | Healthcare | NASDAQ | $8.5M | ||
| INSDInstadose Pharma Corp. | Healthcare | OTC | $53,193 | ||
| IPSEFIpsen S.A. | Healthcare | OTC | $9.4B | ||
| IPSEYIpsen S.A. | Healthcare | OTC | $61.0B | ||
| IRWDIronwood Pharmaceuticals, Inc. | Healthcare | NASDAQ | $778.1M | ||
| ISCNFIsracann Biosciences Inc. | Healthcare | OTC | $1,982 | ||
| ISOLFIsodiol International Inc. | Healthcare | OTC | $4,914 | ||
| ITHUFiAnthus Capital Holdings, Inc. | Healthcare | OTC | $34.1M | ||
| IVIXFInvion Limited | Healthcare | OTC | $3.2M | ||
| IVX.AXInvion Limited | Healthcare | ASX | — | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Sunshine Biopharma, Inc., and how their positions are changing. At a $4.2M market value, institutional positions materially move Sunshine Biopharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Sunshine Biopharma, Inc. executives and directors. Shares of Sunshine Biopharma, Inc. have traded between $0.04 and $0.24 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Sunshine Biopharma, Inc.. Coverage tracks Sunshine Biopharma, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Sunshine Biopharma, Inc.